

Press Release

For Immediate Release

Glenmark announces approval and launch of Ashlyna™ Extended-Cycle Oral Contraceptive Tablets in the US

Mumbai , India, February 25, 2015 –Glenmark Generics Inc., USA, the subsidiary of Glenmark Generics Limited today announced the U.S. market approval and introduction of Ashlyna™ (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Extended-Cycle Oral Contraceptive Tablets, the generic equivalent of Seasonique® by Teva Women’s Health.

Seasonique® is indicated for use by women to prevent pregnancy. According to IMS Health sales data for the 12 month period ending December 2014, the Seasonique® market achieved annual sales of approximately \$159.1 million.

Today’s approval marks Glenmark’s 10th oral contraceptive and first extended-cycle oral contraceptive authorized for distribution by the U.S. FDA. Glenmark plans to commence shipping of Ashlyna™ immediately.

Glenmark’s current portfolio consists of 94 products authorized for distribution in the U.S. marketplace and 75 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics Limited

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America and developing an EU presence. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Jason D’Souza / Rajdeep Barooah

Glenmark, Mumbai, India Tel: [+91 22] 40189919/984

Email: corpcomm@glenmarkpharma.com